Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection

There is a critical need for safe and effective drugs for COVID‐19. Only remdesivir has received authorization for COVID‐19 and has been shown to improve outcomes but not decrease mortality. However, the dose of remdesivir is limited by hepatic and kidney toxicity. ACE2 is the critical cell surface...

Descripción completa

Detalles Bibliográficos
Autores principales: Monteil, Vanessa, Dyczynski, Matheus, Lauschke, Volker M, Kwon, Hyesoo, Wirnsberger, Gerald, Youhanna, Sonia, Zhang, Haibo, Slutsky, Arthur S, Hurtado del Pozo, Carmen, Horn, Moritz, Montserrat, Nuria, Penninger, Josef M, Mirazimi, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799356/
https://www.ncbi.nlm.nih.gov/pubmed/33179852
http://dx.doi.org/10.15252/emmm.202013426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7799356/
https://www.ncbi.nlm.nih.gov/pubmed/33179852
http://dx.doi.org/10.15252/emmm.202013426

Ejemplares similares